The Potential Effect of Insulin on AChE and Its Interactions with Rivastigmine In Vitro
There is no definite cure for Alzheimer’s disease (AD) due to its multifactorial origin. Drugs that inhibit acetylcholinesterase (AChE), such as rivastigmine, are promising symptomatic treatments for AD. Emerging evidence suggests that insulin therapy can hinder several aspects of AD pathology. Insu...
Guardado en:
Autores principales: | Tahereh Jamshidnejad-Tosaramandani, Soheila Kashanian, Mahsa Babaei, Mohamed H. Al-Sabri, Helgi B. Schiöth |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/92921d97535b4d4ea6eb9d82c6c12859 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia
por: Kandiah N, et al.
Publicado: (2017) -
The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer’s Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study
por: Yatawara C, et al.
Publicado: (2021) -
New Compounds with Bioisosteric Replacement of Classic Choline Kinase Inhibitors Show Potent Antiplasmodial Activity
por: Francisco José Aguilar-Troyano, et al.
Publicado: (2021) -
Exosome-Mediated Insulin Delivery for the Potential Treatment of Diabetes Mellitus
por: Belén Rodríguez-Morales, et al.
Publicado: (2021) -
L-carnitine supplementation ameliorates insulin resistance in critically ill acute stroke patients: a randomized, double-blinded, placebo-controlled clinical trial
por: Malihe Nejati, et al.
Publicado: (2022)